Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cell > BTLA > SCCHO-ATP110

CHO/Human BTLA Stable Cell Line Development Service

Order Now

  • Description
    The CHO/Human BTLA Stable Cell Line was engineered to express the receptor full length human BTLA (Gene ID: 151888), used to mimic cancer target cells. When co-cultured with human HVEM Reporter Cell, the BTLA/HVEM interaction drives NF-kB-mediated luminescence. Blocking the BTLA/HVEM interaction by either anti-BTLA or anti-HVEM antibodies results in a decrease in luminescence.
  • Application

    • Useful for cell-based BTLA binding assay

    • Useful as BTLA-expressing target cells in reporter gene assay

     BTLA Assay Principles

  • Growth Properties
    Adherent
  • Culture Medium
    F-12K + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 BTLA FACS

Expression analysis of human BTLA on CHO/Human BTLA Stable Cell Line by FACS.
Cell surface staining was performed on CHO/Human BTLA Stable Cell Line or negative control cell using PE-labeled anti human BTLA antibody.

Passage Stability
 BTLA PASSAGE

Passage stability analysis of receptor expression by FACS.
Flow cytometry surface staining of human BTLA on CHO/Human BTLA Stable Cell Line demonstrates consistent mean fluorescent intensity across passage 3-20.

Please contact us if you are interested in related cell pool service.

  • Background
    B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.
  • License Disclosure
    This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $3500.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:5 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message